0 358

Cited 2 times in

Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study

DC Field Value Language
dc.contributor.author박준용-
dc.date.accessioned2020-12-11T07:50:28Z-
dc.date.available2020-12-11T07:50:28Z-
dc.date.issued2020-12-
dc.identifier.issn1352-0504-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180682-
dc.description.abstractThe treatment of multidrug-resistant (MDR) chronic hepatitis B (CHB) is challenging. Herein, we report a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB in a real-life setting. The inclusion criteria comprised patients with resistance to more than two nucleos(t)ide analogue (NA) classes and hepatitis B virus (HBV) DNA level of ≥200 IU/mL. The primary end-point was virologic response (VR), defined as undetectable HBV DNA (<20 IU/mL) after 60 months. A total of 236 patients met the inclusion criteria. The mean HBV DNA level was 4.16 ± 1.44 log IU/mL; 26.7% of patients had liver cirrhosis. Before the initiation of TDF, 33.5%, 44.9% and 21.6% of patients had mutations resistant to L-NA + adefovir, L-NA + entecavir (ETV) and L-NA + adefovir + ETV, respectively. A total of 184 patients received TDF-based combination therapy [TDF + ETV (n = 178) or TDF + L-NA (n = 6)], and 52 patients received TDF monotherapy. In the entire cohort, the VR rates were 77.2%, 89.9% and 92.2% at 12, 36 and 60 months, respectively. The VR rates were not significantly different between the combination therapy and the monotherapy group after 12 (76.2% vs 80.4%, P = .533), 36 (89.8% vs 90.3%, P = 1.000) or 60 (92.9% vs 87.5%, P = .499) months. Also, there was no significant difference in the cumulative VR rates for 5 years between the treatment groups (P = .910). Newly developed antiviral resistance was not observed. TDF-based therapy was effective for the treatment of MDR CHB. The efficacy of TDF monotherapy was not different from that of the TDF-based combination therapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF VIRAL HEPATITIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleTenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHyung Joon Yim-
dc.contributor.googleauthorSang Jun Suh-
dc.contributor.googleauthorYoung Kul Jung-
dc.contributor.googleauthorSeong Gyu Hwang-
dc.contributor.googleauthorYeon Seok Seo-
dc.contributor.googleauthorSoon Ho Um-
dc.contributor.googleauthorSae Hwan Lee-
dc.contributor.googleauthorYoung Seok Kim-
dc.contributor.googleauthorJae Young Jang-
dc.contributor.googleauthorIn Hee Kim-
dc.contributor.googleauthorHyoung Su Kim-
dc.contributor.googleauthorJi Hoon Kim-
dc.contributor.googleauthorYoung Sun Lee-
dc.contributor.googleauthorEileen L Yoon-
dc.contributor.googleauthorMyeong Jun Song-
dc.contributor.googleauthorJun Yong Park-
dc.identifier.doi10.1111/jvh.13363-
dc.contributor.localIdA01675-
dc.relation.journalcodeJ01928-
dc.identifier.eissn1365-2893-
dc.identifier.pmid32706461-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/jvh.13363-
dc.subject.keywordchronic hepatitis B-
dc.subject.keywordmultidrug resistance-
dc.subject.keywordtenofovir-
dc.subject.keywordtherapy-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.affiliatedAuthor박준용-
dc.citation.volume27-
dc.citation.number12-
dc.citation.startPage1306-
dc.citation.endPage1318-
dc.identifier.bibliographicCitationJOURNAL OF VIRAL HEPATITIS, Vol.27(12) : 1306-1318, 2020-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.